The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Exelixis; Genentech; Helsinn Therapeutics; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical
Speakers' Bureau - Helsinn Therapeutics; SERVIER
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Immunovaccine; Loxo/Lilly; Merck; Novocure; Nucana; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical
 
Francesca Avogadri
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Richard Weng
Employment - QED Therapeutics
Consulting or Advisory Role - QED Therapeutics
 
Ai Li
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Carl L. Dambkowski
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
 
Angela Lamarca
Consulting or Advisory Role - Eisai; Ipsen; Nutricia; Nutricia (I); QED Therapeutics; Roche; SERVIER
Speakers' Bureau - Advanced Accelerator Applications; Incyte; Ipsen; Ipsen (I); Merck; Novartis (I); Pfizer; Pfizer (I); QED Therapeutics; SERVIER
Research Funding - Ipsen; Ipsen (I); Roche
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Bayer; Celgene; Delcath Systems; Ipsen; Ipsen (I); Mylan; NanoString Technologies (I); Novartis; Pfizer; Sirtex Medical